Safety and Efficacy of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes Associated With a Del (5q) Cytogenetic Abnormality

This study has been completed.

Study NCT00065156 Information provided by Celgene Corporation

First Received: July 17, 2003 Last Updated: May 5, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	August 2008
Primary Completion Date:	August 2008 (Final data collection date for primary outcome measure)